Pemirolast

Pemirolast (INN) is a mast cell stabilizer used as an anti-allergic drug therapy.^[1][2][3] It is marketed under the tradenames Alegysal and Alamast.

Trade namesAlamast

AHFS/Drugs.comMonograph

Routes of
administrationOral, ophthalmic

ATC code

• none

Quick facts Clinical data, Trade names ...

Pemirolast

Clinical data
Trade names	Alamast
AHFS/Drugs.com	Monograph
Routes of administration	Oral, ophthalmic
ATC code	none
Legal status
Legal status	US: ℞-only In general: ℞ (Prescription only)
Identifiers
IUPAC name 9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one
CAS Number	69372-19-6 Y
PubChem CID	57697
IUPHAR/BPS	7329
DrugBank	DB00885 N
ChemSpider	51990 N
UNII	2C09NV773M
KEGG	D07476 Y
ChEMBL	ChEMBL1201198 N
CompTox Dashboard (EPA)	DTXSID1048338
Chemical and physical data
Formula	C10H8N6O
Molar mass	228.215 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC=CN2C1=NC=C(C2=O)C3=NNN=N3
NY (what is this?)  (verify)

Close

Clinical trials studying treatments for allergic conjunctivitis have found that an ophthalmic solution containing levocabastine with pemirolast potassium may be more effective in alleviating symptoms than levocabastine alone.^[4]

It has also been studied for the treatment of asthma.^[5]

Pemirolast has appeared as a possible candidate for SARS-CoV-2 (COVID-19) spike protein disruption and interference. Such results were ascertained by molecular dynamics calculations executed on the Summit supercomputer. By simulating compounds with FDA or similar regulatory approval, the authors found 4 interfacial molecules that could potentially disrupt the SARS-CoV-2 interface with ACE-2 receptors, suggesting that such small molecules could mitigate SARS-CoV-2 infection. The 4 candidate interfacial molecules included pemirolast, isoniazid pyruvate, nitrofurantoin, and eriodictyol.^[6]